Supplemental table 1- Baseline characteristics, DAA vs IFN group

|  |  |  |  |
| --- | --- | --- | --- |
|  | **DAA group****(n= 34)** | **IFN group****(n= 22)** | **P-value** |
| Age at transplant (years) | 60.2 [58.1;62.5] | 60.3 [54.6;62.4] | 0.55 |
| Gender, n(%) |  |  | 1.00 |
| Female | 6 (17.6%) | 3 (13.6%) |  |
| Male | 28 (82.4%) | 19 (86.4%) |  |
| White race, n(%) | 25 (73.5%) | 18 (81.8%) | 0.69 |
| Diabetes Mellitus, n(%) | 9 (26.5%) | 7 (31.8%) | 0.90 |
|  |  |  |  |
| Deceased donor LT, n(%) | 34 (100%) | 18 (81.8%) | 0.02 |
| MELD score at transplant | 9.00 [8.00;13.5] | 12.5 [8.00;17.8] | 0.17 |
| Wait-list time (years) | 1.16 [0.75;1.38] | 1.1 [0.39;1.25] | 0.07 |
|  |  |  |  |
| Total bilirubin (mg/dL) | 0.80 [0.60;1.62] | 1.15 [0.68;2.75] | 0.39 |
| ALT (U/L) | 32.0 [25.0;57.0] | 35.0 [27.2;40.5] | 0.68 |
| AST (U/L) | 36.0 [25.0;53.2] | 60.5 [46.5;62.2] | 0.01 |
| Alkaline phosphatase (U/L) | 106 [89.2;132] | 148 [113;158] | 0.09 |
| Albumin (g/dL) | 3.50 [3.10;3.80] | 3.60 [3.35;4.00] | 0.22 |
| AFP (ng/dL) | 8.15 [5.20;13.3] | 7.20 [4.00;14.4] | 0.55 |
| WBC (x 109/L) | 5.75 [3.92;6.75] | 4.80 [3.35;5.40] | 0.05 |
| Hemoglobin (g/dL) | 13.0 [11.5;14.2] | 13.0 [11.5;13.9] | 0.99 |
| Platelets (x 109/L) | 82.0 [65.5;118] | 69.0 [45.0;134] | 0.55 |
|  |  |  |  |
| Donor age | 45.3 [31.3;55.6] | 44.4 [32.4;52.7] | 0.87 |
| Donor BMI | 28.2 [23.9;32.8] | 27.3[24.4;28.7] | 0.38 |
| Donor diabetes mellitus | 4 (11.8%) | 0 (0%) | 0.29 |
| DCD donor | 7 (20.6%) | 0 (0%) | 0.08 |
| Cold ischemic time (minutes) | 390 [320;495] | 355 [289;410] | 0.08 |

DAA= Direct-acting anti-viral, IFN= interferon, LT= Liver transplantation, MELD= Model of End-stage Liver Disease, AFP= Alpha-fetoprotein, BMI= Body mass index, DCD= Donation after cardiac death